Is pulmonary embolism recurrence linked with the severity of the first event? A French retrospective cohort study

Emile Ferrari, Etienne Fourrier, Florian Asarisi, Nathan Heme, Nassim Redjimi, Nathalie Berkane, Mohamed Labbaoui, Jean Philippe Breittmayer, Sok Sithikun Bun, Pamela Moceri, Fabien Squara, Emile Ferrari, Etienne Fourrier, Florian Asarisi, Nathan Heme, Nassim Redjimi, Nathalie Berkane, Mohamed Labbaoui, Jean Philippe Breittmayer, Sok Sithikun Bun, Pamela Moceri, Fabien Squara

Abstract

Objectives: Severity of a first pulmonary embolism (PE) is sometimes proposed as a criterion for prolonging anticoagulant treatment. However, little evidence supports this idea. We attempted to determine the connection between severity of first PE and the risk of recurrence.

Participants: Patients admitted with PE between 2012 and 2018 and for whom anticoagulant treatment had been discontinued were followed. PEs were classified according to the severity into the following two groups: those with associated cardiac involvement (increased cardiac biomarker(s) and/or echocardiographic right ventricular dysfunction) and those with no cardiac involvement which were classified as non-severe. Recurrence-free survivals were estimated using the Kaplan-Meier method and compared using the log-rank test.

Results: 417 patients with PEs (186 with cardiac involvement) were followed for at least 1 year after discontinuation of treatment with a mean follow-up of: 3.5±1.9 years. 72 patients (17.3%) experienced venous thromboembolism recurrence: 24 (5.8%), 44 (12 %) and 72 (28.3 %) respectively, at 1, 2 and 5 years. In 63 patients (88%), recurrence was a PE. Mean time to onset of recurrence was 24.9±19.9 months. At 5 years, the recurrence rate is higher when the first PE was associated with cardiac involvement p=0.043. In contrast, in patients with provoked PE, the recurrence rate is higher when the first PE event was associated with cardiac involvement: p=0.032. Multivariate analysis demonstrates that PE severity is an independent factor of recurrence (HR 1.634 (1.015-2.632), p=0.043).

Conclusion: We report for the first time a possible link between a higher recurrence rate and the severity of the first PE. This result which must be confirmed in a dedicated prospective trial could become an important criterion for the duration of anticoagulant therapy after a PE.

Trial registration number: NCT04980924.

Keywords: adult cardiology; echocardiography; thromboembolism.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Study flowchart. PE, pulmonary embolism; VTE, venous thromboembolism.
Figure 2
Figure 2
Recurrence-free survival for VTE according to the severity of first PE. PE, pulmonary embolism; VTE, venous thromboembolism.
Figure 3
Figure 3
Recurrence-free survival following provoked PE according to the severity of first PE. PE, pulmonary embolism.
Figure 4
Figure 4
Recurrence-free survival following unprovoked PE according to the severity of first PE. PE, pulmonary embolism.

References

    1. Kyrle PA, Minar E, Bialonczyk C, et al. . The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004;350:2558–63. 10.1056/NEJMoa032959
    1. Prandoni P, Noventa F, Ghirarduzzi A, et al. . The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007;92:199–205. 10.3324/haematol.10516
    1. Linnemann B, Zgouras D, Schindewolf M, et al. . Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism: results from the German MAISTHRO registry. Blood Coagul Fibrinolysis 2008;19:159–65. 10.1097/MBC.0b013e3282f54558
    1. Baudouy D, Moceri P, Chiche O, et al. . B blood group: a strong risk factor for venous thromboembolism recurrence. Thromb Res 2015;136:107–11. 10.1016/j.thromres.2015.05.002
    1. Palareti G, Cosmi B, Legnani C, et al. . D-Dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006;355:1780–9. 10.1056/NEJMoa054444
    1. Eichinger S, Minar E, Bialonczyk C, et al. . D-Dimer levels and risk of recurrent venous thromboembolism. JAMA 2003;290:1071–4. 10.1001/jama.290.8.1071
    1. Ferrari E, Baudouy M, Cerboni P, et al. . Clinical epidemiology of venous thromboembolic disease. Results of a French multicentre registry. Eur Heart J 1997;18:685–91. 10.1093/oxfordjournals.eurheartj.a015316
    1. Kearon C, Ageno W, Cannegieter SC, et al. . Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 2016;14:1480–3. 10.1111/jth.13336
    1. Konstantinides SV, Meyer G, Becattini C, et al. . 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory Society (ERS). Eur Heart J 2020;41:543–603. 10.1093/eurheartj/ehz405
    1. Kearon C, Iorio A, Palareti G, et al. . Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. J Thromb Haemost 2010;8:2313–5. 10.1111/j.1538-7836.2010.03991.x
    1. Tromeur C, Sanchez O, Presles E, et al. . Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial. Eur Respir J 2018;51:1701202. 10.1183/13993003.01202-2017
    1. Cohen AT, Gitt AK, Bauersachs R, et al. . The management of acute venous thromboembolism in clinical practice. results from the European prefer in VTe registry. Thromb Haemost 2017;117:1326–37. 10.1160/TH16-10-0793
    1. Khan F, Rahman A, Carrier M, et al. . Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ 2019;366:l4363. 10.1136/bmj.l4363
    1. Martinez C, Cohen AT, Bamber L, et al. . Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. Thromb Haemost 2014;112:255–63. 10.1160/TH13-09-0793
    1. Albertsen IE, Nielsen PB, Søgaard M, et al. . Risk of recurrent venous thromboembolism: a Danish nationwide cohort study. Am J Med 2018;131:1067–74. 10.1016/j.amjmed.2018.04.042
    1. Baglin T, Douketis J, Tosetto A, et al. . Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost 2010;8:2436–42. 10.1111/j.1538-7836.2010.04022.x
    1. Grifoni S, Vanni S, Magazzini S, et al. . Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. Arch Intern Med 2006;166:2151–6. 10.1001/archinte.166.19.2151
    1. Iorio A, Kearon C, Filippucci E, et al. . Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 2010;170:1710–6. 10.1001/archinternmed.2010.367
    1. Prins MH, Lensing AWA, Prandoni P, et al. . Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv 2018;2:788–96. 10.1182/bloodadvances.2018017160
    1. Ensor J, Riley RD, Moore D, et al. . Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. BMJ Open 2016;6:e011190. 10.1136/bmjopen-2016-011190
    1. Bikdeli B, Jimenez D, Hawkins M, et al. . Rationale, design and methodology of the computerized registry of patients with venous thromboembolism (RIETE). Thromb Haemost 2018;118:214–24. 10.1160/TH17-07-0511

Source: PubMed

3
購読する